Poster - #UMDOM106 - Clinical Research and Quality Improvement

CONVALESCENT PLASMA THERAPY IN LATE STAGE, SEVERE COVID-19 INFECTION: A CASE SERIES WITH REVIEW OF THE LITERATURE

Kumar, Neil R. M.D., M.B.A., Karanam, Veena C. B.S., Kumar, Sunil D. M.D.

University of Miami/Jackson Memorial Hospital, University of Miami Miller School of Medicine, Broward Health Medical Center

ABSTRACT
ICU patients received 200ml of plasma in the late stages (after 2 weeks of admission) of COVID-19 infection. Compared to 1 day prior to transfusion, mean SOFA scores, Pao2/Fio2 ratio, GCS scores and lymphocyte count overall improved by day 7. Compared to the SOFA score predicted mortality of 84.4%, mortality of 25% resulted. Therefore, plasma may be safe and effective in late stage, severe COVID-19; however, more than 200ml of plasma transfusion may be necessary for maximum therapeutic effect.